期刊
JOURNAL OF INORGANIC BIOCHEMISTRY
卷 105, 期 11, 页码 1505-1512出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jinorgbio.2011.08.001
关键词
Aluminum toxicity; Alzheimer's disease; Antioxidants; Chelators; Inflammation; Oxidative stress
资金
- NIA NIH HHS [R01 AG038834, R01 AG018031] Funding Source: Medline
In 1991, treatment with low dose intramuscular desferrioxamine (DFO), a trivalent chelator that can remove excessive iron and/or aluminum from the body, was reported to slow the progression of Alzheimer's disease (AD) by a factor of two. Twenty years later this promising trial has not been followed up and why this treatment worked still is not clear. In this critical interdisciplinary review, we provide an overview of the complexities of AD and involvement of metal ions, and revisit the neglected DFO trial. We discuss research done by us and others that is helping to explain involvement of metal ion catalyzed production of reactive oxygen species in the pathogenesis of AD, and emerging strategies for inhibition of metal-ion toxicity. Highlighted are insights to be considered in the quests to prevent potentially toxic effects of aluminum toxicity and prevention and intervention in AD. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据